证券代码：600211 证券简称：西藏药业 公告编号：2023-039 西藏诺迪康药业股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●会议召开时间：2023 年 9 月 14 日 15:00-16:00 ●会议召开方式：本次业绩说明会将采用网络方式举行 ●投资者可于 2023 年 9 月 13 日（星期三）前将相关问题通过电子邮件的形式发送至邮 箱：chenxu@xzyy.cn，本公司将在 2023 年半年度业绩说明会上对投资者普遍关注的问题进行 回答。 本公司已于 2023 年 8 月 25 日在《中国证券报》《上海证券报》《证券时报》及上海证券 交易所网站（www.sse.com.cn）披露公司 2023 年半年度报告，为便于广大投资者更全面深入 了解公司 2023 年半年度的经营成果、财务状况，公司计划于 2023 年 9 月 14 日 15:00-16:00 召开 2023 年半年度业绩说明会，就投资者普遍关心的问题进行交流。 一、说明会类型 ...

西藏诺迪康药业股份有限公司 2023 年第一次临时股东大会文件 1 目 录 | 1、2023年半年度利润分配方案 . | | --- | 2 议案一： 2023 年半年度利润分配方案 各位股东： 公司2023年半年度实现的归属于母公司所有者的净利润为595,904,757.58元（未经审 计）；截止2023年6月30日，公司未分配利润为1,739,842,061.25元。 为了更好地回报投资者，公司结合目前的实际经营状况，拟在2023年半年度进行现金 分红，具体方案如下：以实施利润分配方案之股权登记日可参与分配的总股本为基数，向 全体股东按每10股派发现金12.02元(含税), 合计拟派发现金红利298,021,287.29元（含 税），本半年度公司现金分红比例为50.01%。 如在本方案披露之日起至实施权益分派股权登记日期间，因可转债转股/回购股份/股 权激励授予股份回购注销/重大资产重组股份回购注销等致使公司总股本发生变动的，公司 拟维持现金派发总额不变，相应调整每股分配比例。如后续总股本发生变化，将另行公告 具体调整情况。 上述议案已经公司第八届董事会第二次会议审议通过，并于2023年8月25日在《中国 ...

Financial Performance - The company's revenue increased by 35.52%, while the net profit attributable to shareholders grew by 127.23%[24] - The total profit for the period was 98.89 million RMB, with no adverse factors impacting this figure[24] - The company's revenue for the first half of 2023 reached ¥1,820,236,994.97, representing a 35.52% increase compared to ¥1,343,187,984.10 in the same period last year[46] - Net profit attributable to shareholders for the same period was ¥595,904,757.58, a significant increase of 127.23% from ¥262,250,027.50 year-on-year[46] - Basic earnings per share for the first half of 2023 were ¥2.40, a 126.42% increase from ¥1.06 in the same period last year[46] - The weighted average return on equity increased by 8.73 percentage points to 18.23% compared to 9.50% in the previous year[46] - The company's main business revenue for the first half of 2023 reached CNY 1,817.52 million, a year-on-year increase of 35.52%[51] - The net profit attributable to shareholders for the same period was CNY 595.90 million, reflecting a significant growth of 127.23% year-on-year[51] Production and Capacity - The company has modern production lines for various dosage forms, ensuring sufficient capacity for sales growth[30] - The company is expanding the production capacity of its main product, Xinhua Su, to reach an annual capacity of 15 million units, with construction and equipment debugging completed[76] - The production model is based on "sales-driven production," aligning production plans with annual sales forecasts from distributors[48] Research and Development - The main product, Xinhuisu, is a unique gene-engineered drug for treating acute heart failure, with increasing sales and a competitive advantage in the market[30] - The company has introduced new product forms, such as the granule version of Nuodikan, which offers better absorption and bioavailability[30] - The company is actively researching artificial cultivation techniques for endangered Tibetan medicinal materials, ensuring long-term resource availability[30] - The company has initiated research on the artificial cultivation of other Tibetan medicinal materials, such as Hongjing Tian[55] - The company is conducting research on artificial cultivation of Rhodiola and other Tibetan medicinal materials, with multiple suitable varieties identified for introduction[80] Marketing and Brand Development - The marketing system is well-established nationwide, providing effective support for market competitiveness[30] - The company is actively promoting brand awareness through sponsorship of national sports events, enhancing product visibility[57] - The company has been recognized as the first high-tech pharmaceutical listed company in Tibet and has built three GMP-compliant production bases[49] Financial Management - Financial expenses decreased by 20.77 million RMB year-on-year, primarily due to rising interest income from USD deposits[24] - The company's total assets increased by 18.30% to ¥4,849,558,902.31 compared to ¥4,099,412,305.94 at the end of the previous year[46] - The net cash flow from operating activities was ¥544,852,090.83, up 14.66% from ¥475,187,904.79 in the previous year[46] - The company's trading financial assets increased by 33.77% to ¥1,060,076,514.14 from ¥792,490,921.85 year-on-year[86] - The company’s investment activities generated a net cash outflow of ¥522,582,953.76, compared to a net outflow of ¥274,449,809.74 in the previous year[82] Environmental Management - The company reported a total wastewater discharge of 0.134 tons for chemical oxygen demand (COD) with a concentration of 17.39 mg/L in the first half of the year[98] - The company has a wastewater treatment capacity of 240 m³/d established in 2002, which is currently stable[99] - The company has implemented an emergency response plan for environmental incidents, which is filed with the environmental protection department[102] - The company has not faced any administrative penalties for environmental issues during the reporting period[102] Investments and Acquisitions - The company has invested a total of ¥746 million in the Sputnik-V vaccine project, with delays in technology transfer and increased uncertainty regarding export sales leading to a provision for impairment losses of ¥327.29 million[109] - The company has obtained sales rights for four in-development products from its investment in Amite, with two products already receiving medical device registration and production licenses, while the other two remain under development[109] Related Party Transactions - The total amount of related party transactions for the period was RMB 969,774,470.80, compared to RMB 698,966,972.75 in the previous period[132] Cash Flow and Assets - The company reported a cash balance of approximately ¥476.78 million, with ¥4 million restricted as a loan guarantee[65] - The company’s cash and cash equivalents stood at RMB 102,199,110.39 as of December 31, 2022[125] - The company’s cash and cash equivalents increased to RMB 2,473,965.67 from RMB 1,167,386.81 at the beginning of the period[168]

关于 2023 年半年度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●每股分配比例：A 股每 10 股派发现金红利 12.02 元(含税)。 ●本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日期将在权益 分派实施公告中明确。 ●在实施权益分派的股权登记日前公司总股本发生变动的，拟维持现金派发总额不变， 相应调整每股派发金额，并将另行公告具体调整情况。 一、利润分配方案内容 公司 2023 年半年度实现的归属于母公司所有者的净利润为 595,904,757.58 元（未经 审计）；截止 2023 年 6 月 30 日，公司未分配利润为 1,739,842,061.25 元。 证券代码：600211 证券简称：西藏药业 公告编号：2023-035 西藏诺迪康药业股份有限公司 1 （一）公司第八届董事会第二次会议以 9 票同意，0 票反对，0 票弃权，审议通过了《2023 年半年度利润分配预案》，本方案符合《公司章程》规定的利润分配政策等相关规定。 （二）独立董事意见：公司为了更 ...

证券代码：600211 证券简称：西藏药业 公告编号：2023-034 1、2023 年半年度报告全文及摘要： 表决结果：同意 3 票，反对 0 票，弃权 0 票，通过该议案。 公司全体监事认真审核了 2023 年半年度报告全文、摘要及相关文件，认为公司 2023 年 半年度报告的编制和审议程序符合相关法律法规、《公司章程》和公司内部管理制度的各项规 定；其内容和格式符合中国证监会和上海证券交易所的各项规定，真实地反映了公司 2023 年 半年度的经营管理和财务状况，未发现参与 2023 年半年度报告编制和审议人员有违反保密规 定的行为。 详见公司同日发布的 2023 年半年度报告全文及摘要。 2、2023 年半年度利润分配预案： 西藏诺迪康药业股份有限公司 第八届监事会第二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、会议召开情况 公司第八届监事会第二次会议通知于 2023 年 8 月 11 日以电邮和短信的方式发出，会议 于 2023 年 8 月 23 日在成都市锦江区三色路 427 号以现场结合通讯 ...

证券代码：600211 证券简称：西藏药业 公告编号：2023-036 召开的日期时间：2023 年 9 月 11 日 14 点 30 分 召开地点：四川省成都市锦江区三色路 427 号公司办公楼会议室 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2023 年 9 月 11 日 至 2023 年 9 月 11 日 股东大会召开日期：2023年9月11日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票系统 (一) 股东大会类型和届次 2023 年第一次临时股东大会 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的方式 (四) 现场会议召开的日期、时间和地点 西藏诺迪康药业股份有限公司 关于召开 2023 年第一次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为 ...

Financial Performance - Revenue for the first quarter reached ¥906,936,646.41, an increase of 38.22% compared to the same period last year[3] - Net profit attributable to shareholders was ¥303,199,537.33, reflecting a growth of 73.59% year-over-year[3] - Net profit after deducting non-recurring gains and losses was ¥292,663,191.66, up 60.31% from the previous year[3] - Basic and diluted earnings per share were both ¥1.22, marking a 74.70% increase compared to the same quarter last year[3] - The company's net profit for Q1 2023 reached CNY 305,515,106.51, a significant increase from CNY 176,249,968.12 in Q1 2022, representing a growth of approximately 73.2%[23] - Total operating revenue for Q1 2023 was CNY 336,808,266.54, compared to CNY 197,920,331.83 in Q1 2022, indicating a year-over-year increase of about 70.1%[23] - The total comprehensive income for Q1 2023 was RMB 334,185,286.51, compared to RMB 171,724,467.56 in Q1 2022, representing a year-over-year increase of approximately 94.5%[45] - Basic and diluted earnings per share for Q1 2023 were both RMB 1.22, up from RMB 0.70 in Q1 2022, indicating a growth of 74.3%[45] Cash Flow and Assets - Operating cash flow for the period was ¥383,734,010.64, representing a 58.30% increase year-over-year[3] - Cash flow from operating activities increased to CNY 974,382,793.17 in Q1 2023, up from CNY 727,580,990.05 in Q1 2022, marking a growth of around 33.9%[24] - The company reported a net cash increase of CNY 97,654,907.96 in cash and cash equivalents for Q1 2023, compared to a decrease of CNY 59,236,552.05 in Q1 2022[29] - The total cash outflow from investing activities was $735.46 million, compared to $400.81 million in the same period last year, resulting in a net cash flow from investing activities of $55.06 million, a significant improvement from a net outflow of $98.06 million in Q1 2022[53] - The cash and cash equivalents at the end of Q1 2023 amounted to $1.47 billion, a significant increase from $928.64 million at the end of Q1 2022[53] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,657,241,109.95, up 13.61% from the end of the previous year[4] - The company's total assets increased to approximately RMB 4.66 billion, up from RMB 4.10 billion in the previous period, representing a growth of about 13.5%[21] - Total current liabilities increased to RMB 1.25 billion, up from RMB 1.03 billion, reflecting a growth of approximately 21.8%[21] - The total liabilities increased to $570.81 million in Q1 2023, compared to $483.45 million in Q1 2022, reflecting a growth of 18.1%[55] - The total equity increased to $3.60 billion in Q1 2023, up from $3.40 billion in Q1 2022, representing a growth of 5.8%[55] Shareholder Information - Total number of common shareholders at the end of the reporting period was 41,195[16] - The largest shareholder, Tibet Kangzhe Enterprise Management Co., Ltd., holds 80,033,379 shares, accounting for 32.28% of total shares[16] Research and Development - Research and development expenses decreased compared to the previous year, contributing to the overall profit growth[14] - Research and development expenses decreased to CNY 4,473,040.54 in Q1 2023 from CNY 9,926,809.57 in Q1 2022, reflecting a reduction of approximately 55.1%[23] Strategic Initiatives - The company has identified potential market expansion opportunities and is focusing on new product development[22] - The company is exploring strategic mergers and acquisitions to enhance its market position[22] - The company has established a cash management strategy to optimize its financial resources[22] - The company plans to continue expanding its market presence and investing in new technologies and products, although specific details were not disclosed in the call[45] - The company is actively exploring new financial products and market expansion strategies, as indicated by its ongoing financial management plans[38]

Financial Performance - The company achieved operating revenue of CNY 2,554,609,066.22 in 2022, representing a year-on-year growth of 19.45%[20] - Net profit attributable to shareholders reached CNY 369,808,047.91, an increase of 76.99% compared to the previous year[20] - The net profit after deducting non-recurring gains and losses was CNY 369,204,785.35, reflecting a significant increase of 453.58% year-on-year[20] - The company's revenue increased by CNY 416.02 million, a growth of 19.45%, primarily due to higher sales of new active ingredients[40] - The company's main business revenue for 2022 reached RMB 2,544.92 million, representing a year-on-year growth of 19.67%[66] - The company reported a basic earnings per share of ¥1.49, a significant increase of 77.38% from ¥0.84 in the previous year[138] - The weighted average return on equity rose to 13.18%, an increase of 5.09 percentage points compared to the previous year[138] - The company reported a significant increase in net cash flow from operating activities, amounting to CNY 837,377.04 million, a year-on-year increase of 128.46%[72] Production and Capacity Expansion - The sales of the main product, New Active Substance, reached 6.16 million units, with sales revenue increasing by 33.71% year-on-year[26] - The company is expanding its production capacity for New Active Substance, with a planned annual capacity of 15 million units[33] - A new production base in Lhasa received its drug production license on February 15, 2022, enhancing the company's production capabilities[33] - The company has established a high-altitude medicinal herb cultivation base in Tibet, successfully reducing the incidence of root rot in Rhodiola rosea and improving survival rates[61] - The company has implemented a production transfer for Yimuduo in the Chinese market, completing the necessary method validation and quality management system setup[61] Research and Development - Research and development expenses rose by CNY 27.27 million, an increase of 44.81%, mainly due to the capitalization of expenses related to a vaccine project[42] - The company’s R&D expenses increased by 44.81% to CNY 88,130.46 million, indicating a strong commitment to innovation[72] - The number of R&D personnel is 37, accounting for 6% of the total workforce[80] - Research and development expenses for vaccine technology transfer amounted to 2,524.33 million RMB, with a decrease of 42.09% compared to the previous period[170] Market and Sales Strategy - The company is actively expanding its online sales channels and optimizing hospital market product offerings[66] - The company plans to expand its market presence and enhance its product offerings in response to favorable industry policies and growing healthcare needs[34] - The company has exclusive marketing rights for four in-development products in China, including biodegradable drug-eluting stents, which are expected to contribute to future revenue growth[111] - The company is focusing on the main business and exploring new sales models in response to national medical reform policies[180] Financial Management - The company received government subsidies amounting to CNY 6.39 million, up from CNY 2.46 million in the previous year[53] - Financial expenses decreased by CNY 2.46 million, influenced by increased interest income and reduced foreign exchange losses[42] - The company reported a significant decrease in accounts payable by 58.26%, totaling ¥42,210,412.37 compared to ¥101,136,917.95 last year, indicating improved cash flow management[104] - The company is actively managing liquidity risk by maintaining sufficient cash and cash equivalents to meet operational needs[152] Product Performance - Sales revenue from the main product, Xinhua Su, accounted for 88.44% of total annual sales, with a year-on-year increase of 33.71%[66] - During the reporting period, Xinhua Su sold 6.16 million units, generating sales revenue of RMB 2,250.85 million, while sales revenue from Yimuduo decreased by 45.20% to RMB 165.32 million[60] - Revenue from cardiovascular treatments reached ¥245,924.75 million, representing a year-over-year increase of 20.65%[117] - Revenue from cold medications surged by 142.58% year-over-year, totaling ¥1,472.37 million, with a gross margin of 88.24%[117] Corporate Recognition and Compliance - The company is recognized as the first high-tech pharmaceutical listed enterprise in Tibet and has established multiple production bases compliant with GMP standards[34] - The company has been awarded "Excellent Unit for National Drug Adverse Reaction Monitoring" for two consecutive years, highlighting its commitment to drug safety[34] - The company has been recognized as the first "Pharmaceutical Standard Research Base" in Tibet by the local drug supervision authority[61] Future Plans - The company plans to continue leveraging its unique ecological resources for the development of traditional Tibetan medicine, ensuring long-term growth[70] - The company plans to enhance its product portfolio through acquisitions of mature drugs and increase R&D efforts for new products[180] - The company plans to distribute cash dividends of 7.46 RMB per 10 shares to all shareholders, based on the total share capital as of the dividend registration date[143]

证券代码：600211 证券简称：西藏药业 公告编号：2023-006 西藏诺迪康药业股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●会议召开时间：2023 年 3 月 16 日 15:00-16:00。 ●会议召开方式：本次业绩说明会将采用网络方式举行。 ●投资者可于 2023 年 3 月 15 日（星期三）前将相关问题通过电子邮件的形式发送至邮 箱：chenxu@xzyy.cn，本公司将在 2022 年度业绩说明会上对投资者普遍关注的问题进行回答。 本公司将于 2023 年 3 月 11 日在《中国证券报》《上海证券报》《证券时报》及上海证券 交易所网站（www.sse.com.cn）披露公司 2022 年年度报告，并将于 2023 年 3 月 16 日 15:00-16:00 召开 2022 年度业绩说明会。 说明会；同时公司将通过该平台及时回答投资者的提问。 一、说明会类型 本次业绩说明会以网络方式召开，公司将针对 2022 年度的经营成果 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥614,958,157.89, representing a year-on-year increase of 17.36%[4] - The net profit attributable to shareholders for Q3 2022 was ¥180,535,996.25, reflecting a significant increase of 50.14% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥178,204,991.39, up by 43.86% year-on-year[4] - Total revenue for the first three quarters of 2022 reached ¥1,958,146,141.99, an increase of 25.3% compared to ¥1,561,918,321.68 in the same period of 2021[29] - The company's net profit for the first three quarters of 2022 reached CNY 446,968,616.30, an increase from CNY 421,642,073.47 in the same period of 2021, representing a growth of approximately 6.5%[32] - The total profit for the period was CNY 512,635,895.59, up from CNY 471,085,009.80 in the previous year, marking an increase of around 8.8%[32] - The company recorded a total profit of ¥521.63 million for the first three quarters of 2022, up 36.5% from ¥382.18 million in 2021[43] Cash Flow - The net cash flow from operating activities for the period was ¥125,909,545.11, marking a substantial increase of 38.74% compared to the previous year[4] - The net cash flow from operating activities for Q3 2022 was $601.1 million, an increase of 38.8% compared to $433.3 million in Q3 2021[35] - The net cash flow from investment activities increased by ¥579 million compared to the previous year, mainly due to the maturity of structured bank deposits[10] - The net cash flow from financing activities decreased by RMB 231 million compared to the same period last year, primarily due to an increase in bank loan repayments by RMB 282 million and a decrease in dividends paid by RMB 43 million[14] - The net cash flow from operating activities decreased to ¥178.01 million in 2022 from ¥347.66 million in 2021, reflecting a decline of 48.9%[45] - The company reported a net cash outflow from investing activities of ¥76.43 million in 2022, a significant improvement from a net outflow of ¥354.30 million in 2021[45] Assets and Liabilities - Total assets at the end of Q3 2022 reached ¥4,328,100,029.27, an increase of 13.82% from the end of the previous year[6] - Current assets as of September 30, 2022, totaled ¥2,710,344,422.08, compared to ¥2,181,906,816.29 at the end of 2021, marking a growth of 24.2%[25] - Total liabilities amounted to ¥1,203,281,204.56, compared to ¥1,157,635,453.49 in the previous year, indicating an increase of 3.9%[27] - The total assets reached $3.75 billion as of September 30, 2022, compared to $3.39 billion at the end of 2021, indicating an increase of 10.8%[41] - The company reported a total liability of $560.0 million as of September 30, 2022, down from $594.7 million at the end of 2021, a decrease of 5.8%[41] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 54,413, with the top ten shareholders holding significant stakes, including Tibet Kangzhe Enterprise Management Co., Ltd. with 32.28%[16] - Tibet Kangzhe Enterprise Management Co., Ltd. holds 80,033,379 shares, while Tibet Huaxi Pharmaceutical Group Co., Ltd. holds 44,072,000 shares, representing 17.78%[16] - The top ten shareholders include both domestic and foreign entities, with significant holdings by domestic non-state-owned legal persons[16] - The company has not disclosed any related party transactions among the top shareholders, except for known agreements among certain entities[17] Research and Development - Research and development expenses increased by 318.18% to ¥6,080.03 million, primarily due to the capitalization of expenses related to the new COVID-19 vaccine project[10] - Research and development expenses increased significantly to CNY 79,908,994.62 from CNY 19,108,743.69, reflecting a growth of approximately 317.5%[32] - Research and development expenses surged to ¥64.14 million in the first three quarters of 2022, compared to only ¥4.98 million in the same period of 2021, indicating a substantial focus on innovation[43] Financial Expenses - The company reported a 32.81% increase in income tax expenses, amounting to an increase of ¥1,622.43 million, driven by higher sales revenue[10] - The company experienced a 348.12% increase in financial expenses, totaling an increase of ¥825.45 million, attributed to new bank loans and foreign exchange losses[10] - The financial expenses, including interest expenses, increased to CNY 10,625,628.75 from CNY 2,371,166.48, reflecting a rise of approximately 348.5%[32] - The financial expenses for the first three quarters of 2022 were ¥857.72 thousand, compared to a financial income of ¥748.38 thousand in the same period of 2021[43] Cash Management and Investments - The company has a total of RMB 39 million in unexpired structured deposits, with no overdue amounts reported[18] - The company has engaged in various structured deposits with multiple banks, with amounts ranging from RMB 1,000 million to RMB 8,000 million and annualized returns between 1.3% and 3.4%[20] - The company’s investment activities generated cash inflows of ¥959.09 million in 2022, a substantial increase from ¥151.52 million in 2021[45] - The company plans to continue its investment strategies and cash management practices to optimize financial performance in the future[18]